Protection of spinal cord ischemic injury with the β-agonist Clenbuterol
© Current Science Ltd 2000
Published: 21 March 2000
We studied Clenbuterol, a selective β-2 agonist, in preventing ischemic injury to the spinal cord.
We used 30 New Zealand rabbits for their unique segmental arterial supply to the spinal cord. Fifteen animals in the study arm were given Clenbuterol 9 mg PO 24 h before clamping. Fifteen (control arm) received water only. Heparin (70 IU/kg) was given 5 min before the incision. Ischemic injury was reproduced by cross-clamping the infrarenal aorta for either 22 or 30 min. Direct aortic blood flow measurements were taken with the transonic flowmeter before and after cross-clamping. Paralysis was assessed by the Tarlov's neurological scale.
All animals (2 control, 2 study arm; n=4) subjected to a clamping time of 30 min developed complete paraplegia. Of the control group with 22-min clamping time 77% developed paraplegia (Tarlov 0, n=9; Tarlov 1, n=1) and 23% did not (Tarlov 3, n=1; Tarlov 4, n=2). In the experimental (Clenbuterol) group with 22-min clamping time 38% developed paraplegia (Tarlov 0, n=3; Tarlov 1, n=2) and 62% did not (Tarlov 3, n=2; Tarlov 4, n=6). A consistent observation was that animals which developed paraplegia had a marked increase in post-declamping blood flow, i.e., hyperperfusion, suggesting that variations in aortic blood flow post-declamping may play a role in the development of paraplegia.